197 related articles for article (PubMed ID: 29956453)
1. Decision-making in drug development using a composite definition of success.
Saint-Hilary G; Robert V; Gasparini M
Pharm Stat; 2018 Sep; 17(5):555-569. PubMed ID: 29956453
[TBL] [Abstract][Full Text] [Related]
2. Predictive probability of success using surrogate endpoints.
Saint-Hilary G; Barboux V; Pannaux M; Gasparini M; Robert V; Mastrantonio G
Stat Med; 2019 May; 38(10):1753-1774. PubMed ID: 30548627
[TBL] [Abstract][Full Text] [Related]
3. Practical experiences of adopting assurance as a quantitative framework to support decision making in drug development.
Crisp A; Miller S; Thompson D; Best N
Pharm Stat; 2018 Jul; 17(4):317-328. PubMed ID: 29635777
[TBL] [Abstract][Full Text] [Related]
4. Optimal planning of phase II/III programs for clinical trials with multiple endpoints.
Kieser M; Kirchner M; Dölger E; Götte H
Pharm Stat; 2018 Sep; 17(5):437-457. PubMed ID: 29700949
[TBL] [Abstract][Full Text] [Related]
5. Better decision making in drug development through adoption of formal prior elicitation.
Dallow N; Best N; Montague TH
Pharm Stat; 2018 Jul; 17(4):301-316. PubMed ID: 29603614
[TBL] [Abstract][Full Text] [Related]
6. Evaluating and utilizing probability of study success in clinical development.
Wang Y; Fu H; Kulkarni P; Kaiser C
Clin Trials; 2013; 10(3):407-13. PubMed ID: 23471634
[TBL] [Abstract][Full Text] [Related]
7. Joint probability of statistical success of multiple phase III trials.
Zhang J; Zhang JJ
Pharm Stat; 2013; 12(6):358-65. PubMed ID: 24106067
[TBL] [Abstract][Full Text] [Related]
8. Improving the assessment of the probability of success in late stage drug development.
Hampson LV; Bornkamp B; Holzhauer B; Kahn J; Lange MR; Luo WL; Cioppa GD; Stott K; Ballerstedt S
Pharm Stat; 2022 Mar; 21(2):439-459. PubMed ID: 34907654
[TBL] [Abstract][Full Text] [Related]
9. Integrating dose estimation into a decision-making framework for model-based drug development.
Dunyak J; Mitchell P; Hamrén B; Helmlinger G; Matcham J; Stanski D; Al-Huniti N
Pharm Stat; 2018 Mar; 17(2):155-168. PubMed ID: 29322659
[TBL] [Abstract][Full Text] [Related]
10. The evolving role of patient preference studies in health-care decision-making, from clinical drug development to clinical care management.
Jackson Y; Janssen E; Fischer R; Beaverson K; Loftus J; Betteridge K; Rhoten S; Flood E; Lundie M
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):383-396. PubMed ID: 31070048
[No Abstract] [Full Text] [Related]
11. Bayesian joint modelling of benefit and risk in drug development.
Costa MJ; Drury T
Pharm Stat; 2018 May; 17(3):248-263. PubMed ID: 29473295
[TBL] [Abstract][Full Text] [Related]
12. A comparison of five approaches to decision-making for a first clinical trial of efficacy.
Kirby S; Chuang-Stein C
Pharm Stat; 2017 Jan; 16(1):37-44. PubMed ID: 27678332
[TBL] [Abstract][Full Text] [Related]
13. Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug development.
Wessels AM; Edgar CJ; Nathan PJ; Siemers ER; Maruff P; Harrison J
Drug Discov Today; 2021 May; 26(5):1330-1336. PubMed ID: 33486115
[TBL] [Abstract][Full Text] [Related]
14. An extension of Bayesian expected power and its application in decision making.
Liu F
J Biopharm Stat; 2010 Sep; 20(5):941-53. PubMed ID: 20721783
[TBL] [Abstract][Full Text] [Related]
15. Risk management frameworks for human health and environmental risks.
Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
[TBL] [Abstract][Full Text] [Related]
16. Clinical trials in critical care: can a Bayesian approach enhance clinical and scientific decision making?
Yarnell CJ; Abrams D; Baldwin MR; Brodie D; Fan E; Ferguson ND; Hua M; Madahar P; McAuley DF; Munshi L; Perkins GD; Rubenfeld G; Slutsky AS; Wunsch H; Fowler RA; Tomlinson G; Beitler JR; Goligher EC
Lancet Respir Med; 2021 Feb; 9(2):207-216. PubMed ID: 33227237
[TBL] [Abstract][Full Text] [Related]
17. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
[TBL] [Abstract][Full Text] [Related]
18. Decision-making when data and inferences are not conclusive: risk-benefit and acceptable regret approach.
Hozo I; Schell MJ; Djulbegovic B
Semin Hematol; 2008 Jul; 45(3):150-9. PubMed ID: 18582621
[TBL] [Abstract][Full Text] [Related]
19. Comparing Go/No-Go Decision-Making Properties Between Single Arm Phase II Trial Designs in Oncology.
Broglio K; Marshall J; Yu B; Frewer P
Ther Innov Regul Sci; 2022 Mar; 56(2):291-300. PubMed ID: 34988927
[TBL] [Abstract][Full Text] [Related]
20. Decision making from Phase II to Phase III and the probability of success: reassured by "assurance"?
Carroll KJ
J Biopharm Stat; 2013; 23(5):1188-200. PubMed ID: 23957523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
